Indrayani Biotech Intrinsic Value
Indrayani Biotech (INDRANIB) median intrinsic value is ₹20.60 from 8 valuation models (range ₹3–₹26), vs current price ₹10.30 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Browse INDRANIB balance sheet details for revenue, profit, balance sheet and cash flow data.
INDRANIB Valuation Methods Summary — DCF, Graham Number & P/E
Indrayani Biotech intrinsic value across 8 models vs current price ₹10.30 — upside/downside and value range per method. For current market price and key ratios, visit INDRANIB share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹4.32 | ₹3.46 - ₹5.18 | -58.1% | EPS: ₹0.36, Sector P/E: 12x |
| Book Value Method | asset | ₹21.74 | ₹19.57 - ₹23.91 | +111.1% | Book Value/Share: ₹21.74, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹20.60 | ₹18.54 - ₹22.66 | +100.0% | Revenue/Share: ₹33.04, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹20.60 | ₹18.54 - ₹22.66 | +100.0% | EBITDA: ₹16.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹25.75 | ₹20.60 - ₹30.90 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹3.09 | ₹2.78 - ₹3.40 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹3.09 | ₹2.78 - ₹3.40 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| Graham Defensive Method | conservative | ₹13.27 | ₹11.94 - ₹14.60 | +28.8% | EPS: ₹0.36, BVPS: ₹21.74 |
INDRANIB Intrinsic Value vs Market Price — All Valuation Models
Indrayani Biotech fair value range ₹3–₹26 vs current market price ₹10.30 across 8 valuation models. Also explore INDRANIB price trends to track price trends across different timeframes.
INDRANIB Intrinsic Value Analysis — Undervalued or Overvalued?
Indrayani Biotech median intrinsic value ₹20.60, current price ₹10.30 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of INDRANIB?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Indrayani Biotech (INDRANIB) is ₹20.60 (median value). With the current market price of ₹10.30, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹3.09 to ₹25.75, indicating ₹3.09 - ₹25.75.
Is INDRANIB undervalued or overvalued?
Based on our multi-method analysis, Indrayani Biotech (INDRANIB) appears to be trading below calculated value by approximately 100.0%.
INDRANIB Financial Health — Key Ratios vs Industry Benchmarks
Indrayani Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.70 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 4.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 7.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.57x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
INDRANIB Cash Flow Quality — Operating & Free Cash Flow
Indrayani Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-7 Cr | ₹-7 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-30 Cr | ₹-38 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹16 Cr | ₹-8 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹4 Cr | ₹4 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |